Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report)’s stock price traded up 8.7% on Tuesday . The company traded as high as $0.11 and last traded at $0.10. 32,615,548 shares changed hands during mid-day trading, an increase of 1,470% from the average session volume of 2,076,846 shares. The stock had previously closed at $0.09.
Petros Pharmaceuticals Stock Performance
The stock has a 50 day moving average price of $0.25 and a two-hundred day moving average price of $0.30. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74. The company has a market capitalization of $1.16 million, a price-to-earnings ratio of -0.02 and a beta of 2.04.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Recommended Stories
- Five stocks we like better than Petros Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Learn Technical Analysis Skills to Master the Stock Market
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
